No. | % | |
---|---|---|
Total patients enrolled | 29 | 100 |
Treated | 27 | 93 |
Age, years | ||
Median | 49 | |
Range | 32–64 | |
Male gender | 24 | 83 |
Zubrod performance status | ||
0 | 7 | 24 |
1 | 18 | 62 |
2 | 4 | 14 |
Child-Pugh classification | ||
A | 29 | 100 |
Hepatitis virus serology | ||
Hepatitis B | 19 | 66 |
Hepatitis C | 0 | 0 |
Prior treatment(s) | ||
Surgery | 2 | 7 |
Transarterial chemoembolization | 16 | 55 |
Pretreatment alpha fetoprotein (AFP) | ||
< 400 ng/mL | 8 | 28 |
400–10,000 ng/mL | 14 | 48 |
> 10,000 ng/mL | 7 | 24 |
Pretreatment laboratory data, mean ± SD | ||
Bilirubin, mg/dL | 0.97 ± 0.34 | |
Albumin, g/dL | 3.17 ± 0.47 | |
Aspartate transaminase, U/L | 71 ± 33 | |
Alanine transaminase, U/L | 42 ± 11 | |
Platelet, × 103/mL | 187.5 ± 54.0 | |
Metastatic site(s) | ||
Abdominal lymph node | 18 | 62 |
Lung | 10 | 35 |
Bone | 11 | 38 |